Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptamer GroupFRA:P0J Return-on-Tangible-Equity is -143.58% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 1,198 Biotechnology companies, Aptamer Group ranks worse than 79.38% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Aptamer Group's annualized net income for the quarter that ended in Dec. 2025 was €-2.62 Mil. Aptamer Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €1.83 Mil. Therefore, Aptamer Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -143.58%.
The historical rank and industry rank for Aptamer Group's Return-on-Tangible-Equity or its related term are showing as below:
FRA:P0J'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -618.83 Med: -159.4 Max: -51.47
Current: -133.16
During the past 6 years, Aptamer Group's highest Return-on-Tangible-Equity was -51.47%. The lowest was -618.83%. And the median was -159.40%.
FRA:P0J's Return-on-Tangible-Equity is ranked worse than 79.38% of 1198
companies
in the Biotechnology industry
Industry Median: -42.305
vs FRA:P0J: -133.16
Aptamer Group (FRA:P0J) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Aptamer Group Return-on-Tangible-Equity Related Terms
Aptamer Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Aptamer Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:P0J vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Aptamer Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptamer Group Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptamer Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Aptamer Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -143.58% mean?
Aptamer Group (FRA:P0J) has a Return-on-Tangible-Equity of -143.58% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aptamer Group and its competitors. According to the industry distribution chart, Aptamer Group ranks #951 out of 1198 companies in the Biotechnology industry, placing it in the top 79.4%.
Is Aptamer Group's Return-on-Tangible-Equity too high?
Aptamer Group's current Return-on-Tangible-Equity is -143.58%. Based on the distribution chart, Aptamer Group ranks #951 out of 1198 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Aptamer Group's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptamer Group ranks #951 out of 1198 companies for Return-on-Tangible-Equity. This places Aptamer Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aptamer Group and its competitors. Aptamer Group's current Return-on-Tangible-Equity is -143.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptamer Group stock overvalued right now?
Aptamer Group (FRA:P0J) has a current Return-on-Tangible-Equity of -143.58%. The current Return-on-Tangible-Equity is -143.58%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Aptamer Group (FRA:P0J), the current Return-on-Tangible-Equity is -143.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses, Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics. The Group represents a single operating segment being research and experimental development of biotechnology. It operates in United Kingdom, Europe, USA and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P0J has been successfully added to your 
